Top Companies in Multiple Myeloma Market by Size, Share, Historical and Future Data & CAGR | Report by Vantage Market Research

Vantage Market Research has recently published a new report on "Multiple Myeloma Market” Global Industry Assessment & Forecast to identify key trends and challenges. The report offers insights into the competitive landscape, prospects, and key investment considerations for businesses operating in Multiple Myeloma market. Some of the key statistics in the report highlight that Global Multiple Myeloma Market was valued at USD 21.6 Billion in 2022 and is projected to reach a value of USD 33.1 Billion by 2030 at a CAGR of 6.3% over the forecast period. The global Multiple Myeloma market will continue to expand due to the rising prevalence of multiple myeloma and increasing awareness among patients for the same.

Request Sample Report of Multiple Myeloma Market @ https://www.vantagemarketresearch.com/multiple-myeloma-market-2142/request-sample

The Global Multiple Myeloma Market is dominated by well-known players like Teva Pharmaceutical Industries Ltd. (Israel), Sanofi S.A (France), F. Hoffmann-La Roche Ltd. (Switzerland), Cipla Inc. (India), Merck & Co. Inc. (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), GlaxoSmithKline PLC (U.K.), Mylan N.V. (U.S.) and Eli Lilly and Company (U.S.).

Let’s Take a Look at the Top Market Players that are Captivating the Multiple Myeloma Market

1. Teva Pharmaceutical Industries Ltd. (Israel)

The company's treatments are targeted toward several therapeutic areas, including oncology, respiratory illnesses, and central nervous system disorders. Copaxone, a medication used to treat multiple sclerosis, and ProAir, a medication used to treat asthma, are two essential items. The business is also working on many biosimilar treatments for multiple myeloma. These include biosimilar variations of medications like rituximab, which is used to treat some forms of non-Hodgkin's lymphoma, and darbepoetin alfa, which is used to treat anaemia in patients with multiple myeloma receiving chemotherapy.

2. Sanofi S.A (France)

The business offers extensive goods, including prescription and OTC medicines. Some of its most well-known medications include Dupixent (dupilumab), a biologic used to treat inflammatory disorders like eczema and asthma, and Lantus (insulin glargine), an insulin used to treat diabetes, Plavix (clopidogrel), an antiplatelet medicine, and Lantus (insulin glargine), an insulin used to treat diabetes. In addition, to treat multiple myeloma, they have created various medications. Darzalex (daratumumab), a medication created with Janssen Biotech, is one of the most noteworthy.

3. F. Hoffmann-La Roche Ltd. (Switzerland)

F. Hoffmann-La Roche Ltd. is a pharmaceutical business specializing in ophthalmology, neuroscience, immunology, oncology, and infectious illnesses. Herceptin, Avastin, Rituxan, Tecentriq, and Tamiflu are a few of Roche's most essential goods. Daratumumab (Darzalex), a monoclonal antibody that targets CD38, a protein located on the surface of myeloma cells, is one of the primary drugs in the market for multiple myeloma. The business also works on alternative multiple myeloma treatments, such as the bispecific antibody mosunetuzumab and the antibody-drug combination polatuzumab vedotin (Polivy).

      4 Cipla Inc. (India)

The business is well-established in several therapeutic fields, including respiratory, anti-infective, cancer, cardiology, and central nervous system disorders (CNS). Cipla, an Indian pharmaceutical company, sells Lenalidomide under the trade name Lenangio for treating multiple myeloma. The business also sells Bortezomib, Thalidomide, and Pomalidomide, along with additional medicines for treating multiple myeloma.

5. Merck & Co. Inc. (U.S.)

Merck & Co. Inc. is a pharmaceutical firm that creates, produces, and sells a variety of prescription medications, vaccines, and items for animal health. Merck is working on numerous medications for the multiple myeloma market, one of which is an anti-BCMA antibody-drug conjugate (ADC) called GSK2857916, which is being created in partnership with GlaxoSmithKline.

6. Bayer AG (Germany)

The business creates, produces, and sells a variety of prescription drugs, over-the-counter medicines, agricultural goods, and other goods for health and well-being. The company is well-established in many therapeutic fields, including haematology, cancer, women's health, and cardiology. Nexavar, a kinase inhibitor used to treat liver, kidney, and thyroid cancer, and Stivarga, a kinase inhibitor used to treat gastrointestinal stromal tumors and colorectal cancer, are two medications in the company's oncology portfolio. In addition, Bayer is working on several medications for the multiple myeloma market, one of which is an investigational treatment named MCLA-145 that is being created in collaboration with the biotech firm Xencor.

7. Novartis AG (Switzerland)

Novartis AG develops, produces, and sells a variety of prescription medications, generics, biosimilars, and consumer healthcare items. Regarding therapeutic specialties, Novartis is well-represented in oncology, cardiology, respiratory medicine, and neurology. For example, Novartis has many medications for treating multiple myeloma, including Farydak (panobinostat). In addition, Istatuximab, a monoclonal antibody that targets a protein on myeloma cells, is one of the multiple myeloma treatments the business has in development.

8. GlaxoSmithKline PLC (U.K.)

The business is well-established in several therapeutic fields, including HIV, vaccines, and respiratory. Drugs like Advair, Breo, and Ventolin, used to treat illnesses including asthma and chronic obstructive pulmonary disease, are part of the product portfolio. In addition, many early-stage programs aimed at multiple myeloma are included in the company's immuno-oncology pipeline, including antibodies that target BCMA. They are also creating a bispecific antibody that targets both CD3 and BCMA, as well as an anti-BCMA antibody-drug conjugate (ADC).

9. Mylan N.V. (U.S.)

The company's product line includes treatments for various ailments, including cardiovascular disease, respiratory problems, infectious diseases, and central nervous system disorders. One of Mylan's flagship products is the EpiPen, which treats severe allergic responses. Another is Advair Diskus, which treats asthma and chronic obstructive pulmonary disease (COPD). In addition, the product line offered by Mylan includes generic versions of popular multiple myeloma medications such as bortezomib (Velcade) and lenalidomide (Revlimid).

10. Eli Lilly and Company (U.S.)

Eli Lilly and Company is a worldwide pharmaceutical company that makes, produces, and sells a variety of prescription medications and other healthcare items. The company is prevalent in various therapeutic fields, including those treating cardiovascular disease, diabetes, cancer, immunology, and the immune system. The business sells Empliciti (elotuzumab), a monoclonal antibody that targets the SLAMF7 protein expressed on the surface of multiple myeloma cells in the multiple myeloma market.

Read Our Latest Blog: Top Companies in Food Preservatives Market

Do You Have Any Queries or Specific Requirements? You may enquire to our sales team before purchasing.

Contact us

Eric Kunz

6218 Georgia Avenue NW Ste 1 - 564

Washington DC 20011-5125

United States Tel: +1 202 380 9727

Email: [email protected]

Website: Vantage Market Research

Vantage Market Research Blogs